Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Blueprint Medicines Corporation is a global biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies in allergy/inflammation and oncology/hematology. Its core products include AYVAKIT/AYVAKYT (avapritinib) for systemic mastocytosis and PDGFRA-mutant gastrointestinal stromal tumors. Leveraging proprietary drug design and research platforms, Blueprint targets disease drivers with small molecule inhibitors and protein degraders, serving patients worldwide through integrated R&D, clinical development, and commercial operations.
This description was generated via AI from an annual report. Updated about 1 year ago.